Comparative Pharmacology
Head-to-head clinical analysis: BANAN versus CEFAZOLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BANAN versus CEFAZOLIN.
BANAN vs Cefazolin
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BANAN is a potassium-channel opener that hyperpolarizes smooth muscle cells, leading to vasodilation and reduced peripheral vascular resistance.
Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and disrupting peptidoglycan cross-linking. This leads to cell lysis and death primarily in susceptible gram-positive bacteria.
500 mg orally twice daily for 7-14 days.
1-2 g IV/IM every 6-8 hours; maximum 12 g/day.
None Documented
None Documented
2.5 hours (normal renal function); prolonged to 6-8 hours in severe renal impairment
Clinical Note
moderateCefazolin + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Cefazolin."
Clinical Note
moderateCefazolin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefazolin."
Clinical Note
moderateCefazolin + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefazolin."
Clinical Note
moderatePhenytoin + Cefazolin
1.8 hours in normal renal function; extends to 30–70 hours in end-stage renal disease (CrCl <10 mL/min).
Renal: 70% unchanged; biliary: 20%; fecal: 10%
Renal: 80–90% unchanged via glomerular filtration and tubular secretion; biliary: <1%; fecal: negligible.
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"The protein binding of Cefazolin can be decreased when combined with Phenytoin."